A wearable artificial kidney for patients with end-stage renal disease
Comprehensive Overview
This study, published in JCI Insight (2016), tested whether a new portable, battery-powered dialysis device, worn like a belt, could safely and effectively filter a patient's blood continuously over a full 24-hour period, potentially freeing people with kidney failure from being tethered to a stationary dialysis machine several times a week. Researchers conducted an FDA-approved clinical trial in patients with end-stage renal disease already receiving standard in-center hemodialysis. Of 411 people initially screened, just 7 ultimately enrolled and were connected to the wearable device following a brief conventional dialysis session, with the goal of wearing it continuously for 24 hours in a closely monitored hospital setting while eating, drinking, and moving around normally. Researchers tracked whether the device could keep blood chemistry, fluid balance, and vital signs stable, and separately asked patients how satisfied they were with the experience compared to their usual treatment. Five of the seven participants completed the full 24 hours of continuous wear; the trial was stopped after the seventh participant because of recurring technical problems with the device, including gas bubbles building up in the tubing and inconsistent blood and fluid flow rates. Despite these mechanical issues, the device performed well physiologically whenever it was running.
Outcomes and Implications
The most notable finding was that despite the device's mechanical problems, it successfully cleared waste products from the blood and kept patients' fluid and electrolyte levels stable throughout treatment, with no serious adverse events, showing that the core concept of a continuously worn dialysis device is medically sound. Blood levels of urea, a key marker of waste buildup, were significantly lower during wearable device treatment than during a comparable period of conventional dialysis, as were levels of a larger waste molecule linked to long-term dialysis complications, suggesting the continuous approach may clear toxins at least as effectively as standard treatment despite much slower flow rates. Patients also reported substantially higher satisfaction with the wearable device than with their usual dialysis care, rating it more favorably across most measured categories, including comfort, flexibility, freedom of movement, and willingness to continue treatment. However, the trial also revealed that the current prototype is not yet ready for wider use: recurring issues such as gas bubbles accumulating in the tubing and unpredictable fluid flow forced researchers to halt the study early, underscoring that engineering redesign is needed before the device could be used safely outside a monitored hospital setting. Conventional dialysis, while effective, requires patients to remain connected to stationary machines for hours several times weekly, limiting mobility and quality of life. The authors conclude that this trial offers proof of concept that a wearable artificial kidney could eventually become a viable alternative to conventional hemodialysis, pending further redesign and longer-term testing.